DK1367057T3 - Epothiloner E og F - Google Patents

Epothiloner E og F

Info

Publication number: DK1367057T3
Authority: DK; Denmark
Prior art keywords: methanol; epothilone; resin; extract; reducing
Prior art date: 1996-11-18

Application number

DK03016552T

Other languages

English (en)

Inventor

Hans Reichenbach

Gerhard Hoefle

Klaus Gerth

Heinrich Steinmetz

Original Assignee

Biotechnolog Forschung Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-18

Filing date

1997-11-18

Publication date

2009-01-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26031383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1367057(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-18 Application filed by Biotechnolog Forschung Gmbh filed Critical Biotechnolog Forschung Gmbh

2009-01-19 Application granted granted Critical

2009-01-19 Publication of DK1367057T3 publication Critical patent/DK1367057T3/da

Links

HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title abstract 3
229930013356 epothilone Natural products 0.000 title abstract 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 12
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
239000011347 resin Substances 0.000 abstract 3
229920005989 resin Polymers 0.000 abstract 3
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 abstract 2
QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 abstract 1
229920005654 Sephadex Polymers 0.000 abstract 1
239000012507 Sephadex™ Substances 0.000 abstract 1
241000862997 Sorangium cellulosum Species 0.000 abstract 1
238000010521 absorption reaction Methods 0.000 abstract 1
238000004587 chromatography analysis Methods 0.000 abstract 1
QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 abstract 1
150000003883 epothilone derivatives Chemical class 0.000 abstract 1
238000002955 isolation Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000000926 separation method Methods 0.000 abstract 1
238000000638 solvent extraction Methods 0.000 abstract 1
238000005406 washing Methods 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biotechnology (AREA)
Environmental Sciences (AREA)
Dentistry (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Oncology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Silicon Polymers (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Epoxy Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK03016552T 1996-11-18 1997-11-18 Epothiloner E og F DK1367057T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19647580		1996-11-18
DE19707506		1997-02-25
PCT/EP1997/006442 WO1998022461A1 (de)	1996-11-18	1997-11-18	Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel

Publications (1)

Publication Number	Publication Date
DK1367057T3 true DK1367057T3 (da)	2009-01-19

Family

ID=26031383

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03016552T DK1367057T3 (da)	1996-11-18	1997-11-18	Epothiloner E og F
DK97951233T DK0941227T5 (da)	1996-11-18	1997-11-18	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK97951233T DK0941227T5 (da)	1996-11-18	1997-11-18	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel

Country Status (23)

Country	Link
US (6)	US7067544B2 (da)
EP (2)	EP1367057B1 (da)
JP (1)	JP4274583B2 (da)
KR (1)	KR100538095B1 (da)
CN (2)	CN1196698C (da)
AT (2)	ATE408612T1 (da)
AU (1)	AU753546B2 (da)
BR (1)	BR9713363B1 (da)
CA (1)	CA2269118C (da)
CY (1)	CY2542B1 (da)
CZ (2)	CZ296164B6 (da)
DE (2)	DE59712968D1 (da)
DK (2)	DK1367057T3 (da)
ES (2)	ES2312695T3 (da)
HU (1)	HU229833B1 (da)
IL (1)	IL129558A (da)
NO (1)	NO319984B1 (da)
NZ (1)	NZ335383A (da)
PL (1)	PL193229B1 (da)
PT (2)	PT941227E (da)
RU (1)	RU2198173C2 (da)
TW (1)	TW408119B (da)
WO (1)	WO1998022461A1 (da)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1186606T4 (da)	1995-11-17	2011-12-05	Biotechnolog Forschung Gmbh	Epothilonderivater, deres fremstilling og anvendelse
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
DK1367057T3 (da)	1996-11-18	2009-01-19	Biotechnolog Forschung Gmbh	Epothiloner E og F
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en)	1996-12-03	1999-01-14	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en)	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6441186B1 (en) *	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en) *	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6320045B1 (en)	1997-12-04	2001-11-20	Bristol-Myers Squibb Company	Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) *	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
US6399638B1 (en)	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
DE19820599A1 (de)	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
NZ508326A (en) *	1998-06-18	2003-10-31	Novartis Ag	A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
DE19826988A1 (de)	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
DE19846493A1 (de) *	1998-10-09	2000-04-13	Biotechnolog Forschung Gmbh	DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen
NZ511722A (en)	1998-11-20	2004-05-28	Kosan Biosciences Inc	Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
US6780620B1 (en)	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
HK1040739A1 (zh) *	1998-12-23	2002-06-21	Bristol-Myers Squibb Company	微生物转形方法，用以制造epothilone
US6596875B2 (en)	2000-02-07	2003-07-22	James David White	Method for synthesizing epothilones and epothilone analogs
BR0008379A (pt)	1999-02-22	2002-09-24	Biotechnolog Forschung Gmbh	Epotilonas modificadas em c-21
US6291684B1 (en)	1999-03-29	2001-09-18	Bristol-Myers Squibb Company	Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
PL215901B1 (pl)	1999-04-15	2014-02-28	Bristol Myers Squibb Co	Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
US6593115B2 (en)	2000-03-24	2003-07-15	Bristol-Myers Squibb Co.	Preparation of epothilone intermediates
US6589968B2 (en)	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
EP1652926B1 (en) *	2000-04-28	2009-09-30	Kosan Biosciences, Inc.	Crystalline epothilone d
US6998256B2 (en)	2000-04-28	2006-02-14	Kosan Biosciences, Inc.	Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
UA75365C2 (en) *	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) *	2000-12-07	2001-01-24	Novartis Ag	Organic compounds
NZ526871A (en)	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
IL156580A0 (en)	2001-01-25	2004-01-04	Bristol Myers Squibb Co	A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
HU229349B1 (en)	2001-01-25	2013-11-28	Bristol Myers Squibb Co	Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
US6893859B2 (en)	2001-02-13	2005-05-17	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
BR0207487A (pt)	2001-02-20	2004-08-10	Brystol Myers Squibb Company	Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
PL363363A1 (en)	2001-02-20	2004-11-15	Bristol-Myers Squibb Company	Epothilone derivatives for the treatment of refractory tumors
AU2002308218B2 (en)	2001-02-27	2005-11-10	Novartis Ag	Combination comprising a signal transduction inhibitor and an epothilone derivative
KR20030084952A (ko)	2001-02-27	2003-11-01	게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프)	에포틸론의 분해 및 에티닐 치환된 에포틸론
WO2002072085A1 (en)	2001-03-14	2002-09-19	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA03010909A (es)	2001-06-01	2004-02-17	Bristol Myers Squibb Co	Derivados de epotilona.
TWI315982B (en)	2001-07-19	2009-10-21	Novartis Ag	Combinations comprising epothilones and pharmaceutical uses thereof
DE10138347A1 (de) *	2001-08-03	2003-02-27	Schering Ag	Geschützte 3,5-Dihydroxy-2,2-dimethyl-valeronitrile für die Synthese von Epothilonen- und Derivaten und Verfahren zur Herstellung
TWI287986B (en) *	2001-12-13	2007-10-11	Novartis Ag	Use of Epothilones for the treatment of the carcinoid syndrome
US6884608B2 (en)	2001-12-26	2005-04-26	Bristol-Myers Squibb Company	Compositions and methods for hydroxylating epothilones
AU2003235761A1 (en)	2002-01-14	2003-07-24	Novartis Ag	Combinations comprising epothilones and anti-metabolites
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
SI1483251T1 (sl)	2002-03-12	2010-03-31	Bristol Myers Squibb Co	C cian epotilonski derivati
AU2003218107A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
TW200403994A (en)	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en)	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003251902B2 (en) *	2002-07-29	2008-03-06	Merck Sharp & Dohme Llc	Tiacumicin production
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de) *	2002-08-23	2010-01-14	Sloan Kettering Inst Cancer	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
BRPI0314133A8 (pt)	2002-09-23	2017-09-19	Bristol Myers Squibb Co	Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
CA2501717C (en) *	2002-10-15	2012-09-18	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Use of epothilone derivatives for the treatment of hyperparathyroidism
US7632858B2 (en)	2002-11-15	2009-12-15	Bristol-Myers Squibb Company	Open chain prolyl urea-related modulators of androgen receptor function
CN101177425B (zh) *	2003-01-28	2012-07-18	北京华昊中天生物技术有限公司	一类新型埃坡霉素化合物及其制备方法和用途
US20050171167A1 (en)	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
RS52545B (sr)	2004-04-07	2013-04-30	Novartis Ag	Inhibitori protein apoptoze (iap)
US10675326B2 (en)	2004-10-07	2020-06-09	The Board Of Trustees Of The University Of Illinois	Compositions comprising cupredoxins for treating cancer
EP1824458A1 (en) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
AR052142A1 (es) *	2004-11-18	2007-03-07	Bristol Myers Squibb Co	Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
JP2009510073A (ja)	2005-09-27	2009-03-12	ノバルティスアクチエンゲゼルシャフト	カルボキシアミン化合物およびその使用方法
RU2487711C2 (ru)	2005-11-21	2013-07-20	Новартис Аг	Лечение нейроэндокринных опухолей
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
US20110104664A1 (en)	2006-03-31	2011-05-05	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
EP2606890A1 (en)	2006-04-05	2013-06-26	Novartis AG	Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
CA2645633A1 (en)	2006-04-05	2007-11-01	Novartis Ag	Combinations of therapeutic agents for treating cancer
MX2008014292A (es)	2006-05-09	2008-11-18	Novartis Ag	Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
WO2008037477A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as p13k lipid kinase inhibitors
MX2009005849A (es)	2006-12-04	2009-08-12	Univ Illinois	Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
KR20090114414A (ko)	2007-02-08	2009-11-03	더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이	쿠프레독신으로 암을 예방하는 조성물과 방법
BRPI0807812A2 (pt)	2007-02-15	2020-06-23	Novartis Ag	Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
WO2009118292A1 (en)	2008-03-24	2009-10-01	Novartis Ag	Arylsulfonamide-based matrix metalloprotease inhibitors
NZ588069A (en)	2008-03-26	2012-06-29	Novartis Ag	Hydroxamate-based inhibitors of deacetylases b
CN101362784A (zh) *	2008-10-06	2009-02-11	山东大学	埃博霉素苷类化合物和以其为活性成分的组合物及其应用
WO2010083617A1 (en)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines as protein kinase inhibitors
PT2391366E (pt)	2009-01-29	2013-02-05	Novartis Ag	Benzimidazoles substituídos para o tratamento de astrocitomas
UY32730A (es)	2009-06-26	2011-01-31	Novartis Ag	Inhibidores de cyp17
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja)	2009-08-12	2015-09-24	ノバルティスアーゲー	ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5775871B2 (ja)	2009-08-20	2015-09-09	ノバルティスアーゲー	ヘテロ環式オキシム化合物
WO2011023677A1 (en)	2009-08-26	2011-03-03	Novartis Ag	Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
JP5466767B2 (ja)	2009-11-04	2014-04-09	ノバルティスアーゲー	Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
CA2781218A1 (en)	2009-12-08	2011-06-16	Novartis Ag	Heterocyclic sulfonamide derivatives
CU24130B1 (es)	2009-12-22	2015-09-29	Novartis Ag	Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
AU2011255647A1 (en)	2010-05-18	2012-11-15	Cerulean Pharma Inc.	Compositions and methods for treatment of autoimmune and other diseases
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
US8946260B2 (en)	2010-09-16	2015-02-03	Novartis Ag	17α-hydroxylase/C17,20-lyase inhibitors
CN103442737B (zh)	2011-01-20	2017-03-29	得克萨斯系统大学董事会	Mri标记、递送和提取系统及其制造方法和用途
WO2012107500A1 (en)	2011-02-10	2012-08-16	Novartis Ag	[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
AU2012249421B9 (en)	2011-04-28	2015-10-22	Novartis Ag	17alpha-hydroxylase/C17,20-lyase inhibitors
BR112013031201A2 (pt)	2011-06-09	2017-01-31	Novartis Ag	derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit
WO2012171020A1 (en)	2011-06-10	2012-12-13	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
WO2012175520A1 (en)	2011-06-20	2012-12-27	Novartis Ag	Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en)	2011-06-20	2015-04-29	Novartis AG	Cyclohexyl isoquinolinone compounds
JP2014518256A (ja)	2011-06-27	2014-07-28	ノバルティスアーゲー	テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
EA026655B1 (ru)	2011-09-15	2017-05-31	Новартис Аг	6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
JP5992054B2 (ja)	2011-11-29	2016-09-14	ノバルティスアーゲー	ピラゾロピロリジン化合物
JP5903499B2 (ja)	2011-12-22	2016-04-13	ノバルティスアーゲー	ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
WO2013093850A1 (en)	2011-12-22	2013-06-27	Novartis Ag	Quinoline derivatives
EP2794592A1 (en)	2011-12-23	2014-10-29	Novartis AG	Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794588A1 (en)	2011-12-23	2014-10-29	Novartis AG	Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015442A8 (pt)	2011-12-23	2017-07-04	Novartis Ag	compostos e composições para inibir a interação de bcl2 com parceiros de ligação
JP2015503518A (ja)	2011-12-23	2015-02-02	ノバルティスアーゲー	Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
MX2014007732A (es)	2011-12-23	2015-01-12	Novartis Ag	Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace.
KR101372563B1 (ko)	2011-12-26	2014-03-14	주식회사 삼양바이오팜	에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법
US8815926B2 (en)	2012-01-26	2014-08-26	Novartis Ag	Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
KR20150008406A (ko)	2012-05-15	2015-01-22	노파르티스 아게	Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
ES2670667T3 (es)	2012-05-15	2018-05-31	Novartis Ag	Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
PT2861579T (pt)	2012-05-15	2018-04-27	Novartis Ag	Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
WO2013171641A1 (en)	2012-05-15	2013-11-21	Novartis Ag	Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
EP2855483B1 (en)	2012-05-24	2017-10-25	Novartis AG	Pyrrolopyrrolidinone compounds
JP6427097B2 (ja)	2012-06-15	2018-11-21	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	癌を処置するための組成物および該組成物を製造するための方法
RS55764B1 (sr)	2012-10-02	2017-07-31	Gilead Sciences	Inhibitori histonskih demetilaza
CN104768962B (zh)	2012-11-17	2017-04-05	北京市丰硕维康技术开发有限责任公司	离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
CA2892863C (en)	2012-12-10	2022-03-15	Mersana Therapeutics, Inc.	Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en)	2012-12-12	2014-06-19	Mersana Therapeutics,Inc.	Hydroxy-polmer-drug-protein conjugates
JO3464B1 (ar)	2013-01-15	2020-07-05	Astellas Pharma Europe Ltd	التركيبات الخاصة بمركبات التياكوميسين
WO2014115080A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en)	2013-01-22	2016-08-02	Novartis Ag	Substituted purinone compounds
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
CA2901022C (en)	2013-02-27	2021-05-04	Epitherapeutics Aps	Substituted pyridine compounds as inhibitors of histone demethylases
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
HK1219879A1 (zh)	2013-06-11	2017-04-21	Bayer Pharma Aktiengesellschaft	用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
WO2015022664A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
US9657007B2 (en)	2013-09-22	2017-05-23	Calitor Sciences, Llc	Substituted aminopyrimidine compounds and methods of use
EA032231B1 (ru)	2013-10-11	2019-04-30	Мерсана Терапьютикс, Инк.	Конъюгаты белок-полимер-лекарственное средство
CA2927022C (en)	2013-10-11	2018-08-21	Asana Biosciences, Llc	Protein-polymer-drug conjugates
MX2016012574A (es)	2014-03-28	2017-09-26	Calitor Sciences Llc	Compuestos heteroarilo sustituidos y metodos de uso.
EP3126345A1 (en)	2014-03-31	2017-02-08	Gilead Sciences, Inc.	Inhibitors of histone demethylases
KR20160132496A (ko)	2014-04-03	2016-11-18	인빅터스 온콜로지 피비티. 엘티디.	초분자 조합 치료제
SG11201701182VA (en)	2014-08-27	2017-03-30	Gilead Sciences Inc	Compounds and methods for inhibiting histone demethylases
WO2017044434A1 (en)	2015-09-11	2017-03-16	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
US11617799B2 (en)	2016-06-27	2023-04-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
JP7320458B2 (ja)	2017-06-22	2023-08-03	メルサナセラピューティクスインコーポレイテッド	薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
US10683297B2 (en)	2017-11-19	2020-06-16	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
AU2019209960B2 (en)	2018-01-20	2023-11-23	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine compounds and methods of use
ES2975330T3 (es)	2018-05-04	2024-07-04	Tagworks Pharmaceuticals B V	Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
EP3787691A1 (en)	2018-05-04	2021-03-10	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
AU2019369340A1 (en)	2018-10-29	2021-05-20	Mersana Therapeutics, Inc.	Cysteine engineered antibody-drug conjugates with peptide-containing linkers
FR3087650B1 (fr)	2018-10-31	2021-01-29	Bio Even	Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
EP4382129A3 (en)	2019-06-17	2024-07-03	Tagworks Pharmaceuticals B.V.	Compounds for fast and efficient click release
JP2024532537A (ja)	2021-09-06	2024-09-05	ヴェラクサバイオテックゲーエムベーハー	真核生物における遺伝暗号の拡張のための新規アミノアシルｔＲＮＡ合成酵素変異体
CA3238627A1 (en)	2021-11-25	2023-06-01	Christine Kohler	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
ES3039688T3 (en)	2021-11-25	2025-10-23	Veraxa Biotech Gmbh	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
KR20240119102A (ko)	2021-12-08	2024-08-06	유럽피안 몰레큘러 바이올로지 래보러토리	표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
EP4372000A3 (en)	2022-02-15	2024-07-17	Tagworks Pharmaceuticals B.V.	Masked il12 protein
JP2025524728A (ja)	2022-07-15	2025-07-30	フィアンセラピューティクスエルティーディー	抗体－薬物複合体
IL320221A (en)	2022-10-12	2025-06-01	Tagworks Pharmaceuticals B V	Strained bicyclo-nonanes
CN120569216A (zh)	2023-01-20	2025-08-29	巴斯夫欧洲公司	稳定型生物聚合物组合物、其制造和用途
KR20250169530A (ko)	2023-03-10	2025-12-03	태그웍스 파마슈티컬스 비.브이.	개선된 t-링커를 갖는 트랜스-사이클로옥텐
AU2024300552A1 (en)	2023-07-27	2026-01-29	Veraxa Biotech Gmbh	Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
EP4512395A1 (en)	2023-08-21	2025-02-26	Bio Even	Composition comprising flavin adenine dinucleotide (fad), l-gsh, atp and myristic acid, alone or with a drug
WO2025056807A1 (en)	2023-09-15	2025-03-20	Basf Se	Stabilized biopolymer composition, their manufacture and use
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release
WO2026043376A1 (en)	2024-08-22	2026-02-26	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene formulations
WO2026078060A1 (en)	2024-10-08	2026-04-16	Basf Se	Tocopherol alkoxylates for biopolymer stabilization

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0358606A3 (de)	1988-09-09	1990-10-31	Gesellschaft für Biotechnologische Forschung mbH (GBF)	Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer mikrobizider makrozyklischer Lactonderivate
GB8909737D0 (en) *	1989-04-27	1989-06-14	Shell Int Research	Thiazole derivatives
DE4138042C2 (de) *	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP0687174B1 (en)	1993-03-05	2001-06-13	Hexal Ag	Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation
EP0739339A1 (en) *	1994-01-11	1996-10-30	The Scripps Research Institute	Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
DK1186606T4 (da)	1995-11-17	2011-12-05	Biotechnolog Forschung Gmbh	Epothilonderivater, deres fremstilling og anvendelse
DE19542986A1 (de) *	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
EP0923583A1 (de) *	1996-08-30	1999-06-23	Novartis AG	Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DK1367057T3 (da)	1996-11-18	2009-01-19	Biotechnolog Forschung Gmbh	Epothiloner E og F
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) *	1996-12-03	1999-01-14	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
PT975638E (pt) *	1997-02-25	2002-12-31	Biotechnolog Forschung Mbh Gbf	Epothilons modificados nas cadeias laterais
US5828449A (en)	1997-02-26	1998-10-27	Acuity Imaging, Llc	Ring illumination reflective elements on a generally planar surface
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de)	1997-04-18	1998-10-29	Studiengesellschaft Kohle Mbh	Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) *	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6384230B1 (en)	1997-07-16	2002-05-07	Schering Aktiengesellschaft	Thiazole derivatives, method for their production and use
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
SK287775B6 (sk)	1998-02-05	2011-09-05	Novartis Ag	Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de)	1998-02-25	2006-07-20	Sloan-Kettering Institute For Cancer Research	Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
WO2000000485A1 (de)	1998-06-30	2000-01-06	Schering Aktiengesellschaft	Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
NZ511722A (en)	1998-11-20	2004-05-28	Kosan Biosciences Inc	Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) *	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
CN1122668C (zh)	1998-12-22	2003-10-01	诺瓦提斯公司	环氧噻酮衍生物，其制备方法及其药物组合物
US6780620B1 (en) *	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) *	2000-02-07	2003-07-22	James David White	Method for synthesizing epothilones and epothilone analogs
YU59001A (sh)	1999-02-18	2005-07-19	Schering Ag.	16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena
BR0008379A (pt) *	1999-02-22	2002-09-24	Biotechnolog Forschung Gmbh	Epotilonas modificadas em c-21
US6211412B1 (en) *	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
US6489314B1 (en) *	2001-04-03	2002-12-03	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
US6589968B2 (en) *	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
US6906188B2 (en) *	2001-04-30	2005-06-14	State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Method for synthesizing epothilones and epothilone analogs
WO2003029195A1 (en) *	2001-09-28	2003-04-10	Sumika Fine Chemicals Co., Ltd.	Intermediates for epothilone derivative and process for producing these
US6884608B2 (en) *	2001-12-26	2005-04-26	Bristol-Myers Squibb Company	Compositions and methods for hydroxylating epothilones
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
US6921769B2 (en) *	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
BRPI0314133A8 (pt)	2002-09-23	2017-09-19	Bristol Myers Squibb Co	Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona

1997
- 1997-11-18 DK DK03016552T patent/DK1367057T3/da active
- 1997-11-18 ES ES03016552T patent/ES2312695T3/es not_active Expired - Lifetime
- 1997-11-18 AU AU54837/98A patent/AU753546B2/en not_active Expired
- 1997-11-18 BR BRPI9713363-9A patent/BR9713363B1/pt not_active IP Right Cessation
- 1997-11-18 KR KR10-1999-7004302A patent/KR100538095B1/ko not_active Expired - Lifetime
- 1997-11-18 CN CNB971998140A patent/CN1196698C/zh not_active Expired - Lifetime
- 1997-11-18 AT AT03016552T patent/ATE408612T1/de active
- 1997-11-18 AT AT97951233T patent/ATE267197T1/de active
- 1997-11-18 DE DE59712968T patent/DE59712968D1/de not_active Expired - Lifetime
- 1997-11-18 CZ CZ0175099A patent/CZ296164B6/cs not_active IP Right Cessation
- 1997-11-18 WO PCT/EP1997/006442 patent/WO1998022461A1/de not_active Ceased
- 1997-11-18 DK DK97951233T patent/DK0941227T5/da active
- 1997-11-18 JP JP52320898A patent/JP4274583B2/ja not_active Expired - Lifetime
- 1997-11-18 ES ES97951233T patent/ES2221692T5/es not_active Expired - Lifetime
- 1997-11-18 HU HU0000497A patent/HU229833B1/hu unknown
- 1997-11-18 RU RU99113031/04A patent/RU2198173C2/ru active
- 1997-11-18 PT PT97951233T patent/PT941227E/pt unknown
- 1997-11-18 CN CNB2005100062827A patent/CN100344627C/zh not_active Expired - Lifetime
- 1997-11-18 NZ NZ335383A patent/NZ335383A/xx not_active IP Right Cessation
- 1997-11-18 EP EP03016552A patent/EP1367057B1/de not_active Expired - Lifetime
- 1997-11-18 PT PT03016552T patent/PT1367057E/pt unknown
- 1997-11-18 DE DE59711647T patent/DE59711647D1/de not_active Expired - Lifetime
- 1997-11-18 IL IL12955897A patent/IL129558A/en not_active IP Right Cessation
- 1997-11-18 EP EP97951233A patent/EP0941227B2/de not_active Expired - Lifetime
- 1997-11-18 CA CA2269118A patent/CA2269118C/en not_active Expired - Lifetime
- 1997-11-18 PL PL333435A patent/PL193229B1/pl unknown
- 1997-11-18 CZ CZ20041118A patent/CZ303422B6/cs not_active IP Right Cessation
1998
- 1998-01-21 TW TW086117334A patent/TW408119B/zh not_active IP Right Cessation
1999
- 1999-05-14 NO NO19992338A patent/NO319984B1/no not_active IP Right Cessation
2004
- 2004-11-12 US US10/988,328 patent/US7067544B2/en not_active Expired - Fee Related
2005
- 2005-10-26 CY CY0500058A patent/CY2542B1/xx unknown
2006
- 2006-04-27 US US11/412,536 patent/US20060264482A1/en not_active Abandoned
2008
- 2008-04-28 US US12/110,781 patent/US20080293784A1/en not_active Abandoned
2009
- 2009-03-24 US US12/409,823 patent/US7846952B2/en not_active Expired - Fee Related
- 2009-05-01 US US12/434,078 patent/US7759375B2/en not_active Expired - Fee Related
2010
- 2010-12-06 US US12/961,447 patent/US8076490B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7067544B2 (en)	2006-06-27
ES2221692T4 (es)	2005-10-01
TW408119B (en)	2000-10-11
WO1998022461A1 (de)	1998-05-28
DE59711647D1 (de)	2004-06-24
CZ303422B6 (cs)	2012-09-05
JP2001504474A (ja)	2001-04-03
EP0941227A1 (de)	1999-09-15
US20050090535A1 (en)	2005-04-28
EP0941227B1 (de)	2004-05-19
IL129558A (en)	2001-10-31
CA2269118A1 (en)	1998-05-28
US20090247592A1 (en)	2009-10-01
NO319984B1 (no)	2005-10-10
US7846952B2 (en)	2010-12-07
EP1367057B1 (de)	2008-09-17
JP4274583B2 (ja)	2009-06-10
US20060264482A1 (en)	2006-11-23
CN1237970A (zh)	1999-12-08
EP1367057A1 (de)	2003-12-03
DE59712968D1 (de)	2008-10-30
US20090270466A1 (en)	2009-10-29
NO992338L (no)	1999-05-14
US7759375B2 (en)	2010-07-20
EP0941227B9 (de)	2005-05-04
HK1022314A1 (en)	2000-08-04
DK0941227T4 (da)	2008-05-19
CA2269118C (en)	2012-05-29
ES2221692T5 (es)	2009-12-14
EP0941227B2 (de)	2009-10-14
DK0941227T5 (da)	2009-10-05
PL333435A1 (en)	1999-12-06
CY2542B1 (en)	2006-06-28
ATE408612T1 (de)	2008-10-15
HUP0000497A2 (hu)	2000-06-28
NZ335383A (en)	2000-10-27
BR9713363A (pt)	2000-01-25
ES2312695T3 (es)	2009-03-01
CN1196698C (zh)	2005-04-13
CN100344627C (zh)	2007-10-24
US8076490B2 (en)	2011-12-13
CN1680370A (zh)	2005-10-12
HUP0000497A3 (en)	2001-10-29
ES2221692T3 (es)	2005-01-01
HK1083832A1 (zh)	2006-07-14
KR100538095B1 (ko)	2005-12-21
BR9713363B1 (pt)	2011-02-08
CZ296164B6 (cs)	2006-01-11
HU229833B1 (en)	2014-09-29
US20080293784A1 (en)	2008-11-27
KR20000053308A (ko)	2000-08-25
CZ175099A3 (cs)	1999-09-15
IL129558A0 (en)	2000-02-29
ATE267197T1 (de)	2004-06-15
NO992338D0 (no)	1999-05-14
AU5483798A (en)	1998-06-10
DK0941227T3 (da)	2004-06-28
PL193229B1 (pl)	2007-01-31
PT1367057E (pt)	2008-12-04
US20110136185A1 (en)	2011-06-09
PT941227E (pt)	2004-08-31
RU2198173C2 (ru)	2003-02-10
AU753546B2 (en)	2002-10-24

Publication	Publication Date	Title
DK1367057T3 (da)	2009-01-19	Epothiloner E og F
DK0643689T3 (da)	1999-08-30	Forbedret fremgangsmåde til syntese af (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoat
DK0553213T3 (da)	1995-07-17	Fremgangsmåde til fremstilling af (4R-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxan- 4-acetat
NO953762D0 (no)	1995-09-22	Innrettet fiberarmert panel for deler av tre
AU2002229639A1 (en)	2002-06-24	Camelidae antibody arrays
WO2004092885A3 (en)	2005-05-06	User interface for controlling a whirlpool tub
WO2002032844A8 (de)	2003-08-21	Epothilone-synthesebausteine iii und iv: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie verfahren zur herstellung von epothilon b, d und epothilonderivaten
ES2160895T3 (es)	2001-11-16	Produccion de un suero proteinico vegetal enriquecido con isoflavonas agluconicas.
Terem et al.	1986	Scalaradial derivatives from the nudibranch Chromodoris youngbleuthi and the sponge Spongia oceania
WO2006061856A3 (en)	2007-07-05	Improved process for purificaton of 6 acetyl 4,1’,6’ trichlorogalactosucrose and 4,1’,6’ trichlorogalactosucrose by chromatography on silanized silica gel
IT1250692B (it)	1995-04-21	Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi.
Mercer et al.	1987	Echinococcus granulosus: occurrence of ecdysteroids in protoscoleces and hydatid cyst fluid
EP1396482A4 (en)	2005-11-16	PROCESS FOR THE PREPARATION OF ADAMANTAN AND ANALOGUE THEREOF
WO1997022769A3 (de)	1997-10-23	Fuss für einen zaunpfahl oder für eine strebe an einem zaunpfahl
LV12433A (lv)	2000-02-20	Arilaminotriazolopiridinu iegusanas panemiens
ES1030366U (es)	1995-08-01	Rebosadero perfeccionado, para bañeras y similares.
WO2004038375A3 (en)	2004-10-07	Water soluble toxin produced by pfiesteria species
DK0538803T3 (da)	1996-06-24	Fremgangsmåde til fremstilling af vinylbenzener
Beran et al.	1990	Preparative high-performance liquid chromatography of minor products of Streptomyces cinnamonensis
WO2000018777A3 (en)	2001-01-04	Method for synthesizing c-glycosides of ulosonic acids
ITMI951184A1 (it)	1996-12-09	Ombrello
ES1023954U (es)	1993-08-01	Cabezal para duchas perfeccionado.
ES1034479U (es)	1997-01-01	Filtro de cubo perfeccionado aplicable en griferia.
IT1287370B1 (it)	1998-08-04	Spaccatrice per pelli con perfezionamenti alla incastellatura.
DK199801009A (da)	1998-08-06	Fremgangsmåde til fremstilling af et naphthalenderivat og naphthalenderivat anvendeligt som mellemprodukt i denne fremgangs